Core Technology

EVIA’s Breakthrough Technology

Related publication (Nature): Click here for details.

Related publication (Cell): Click here for details.

Related publication (eLife): Click here for details.

Related publication (Stem Cell Reports): Click here for details.

Our core technology is cell reprogramming

-a process that reverts mature cells into multi-potent stem cells without genetic modification.

We are the first to successfully reprogram mature hepatocytes into liver progenitor cells (CLiPs) in vitro.

Katsuda et al., 2017, Cell Stem Cell

CLiPs are a type of stem cell with the ability to differentiate into specialized cell types, such as hepatocytes and biliary epithelial cells, in the body.

EVIA plans to leverage its reprogramming platform to build future applications across different cell types.
We aim to develop EV therapeutic candidates made from progenitor cells.
We have already identified target cell candidates and successfully reprogrammed progenitor cells in-vitro.
We plan to expand our drug pipeline and proceed to non-clinical and clinical trials.
Our non-clinical research is being conducted in collaboration with academic institutions, with funding from an AMED grant.

Reprogramming Mature Cells into Progenitor Cells

Evia focuses on reprogramming specified mature cell types into progenitor cells that have increased proliferation capacities.
We have successfully reprogrammed progenitor cells that differentiate into cell types with extremely high regenerative abilities.
By chemically inducing and stimulating mature cells in both humans and animals in vitro, we have shown the ability to induce liver progenitor cells (CLiPs) even from damaged cell sources.
In addition to CLiPs, EVs secreted from CLiPs also have regenerative features that show improvements on hepatic fibrosis and which can be applied to EV drug candidates.

Explore our Pipeline: Click here